ArchiMed, a Lyon, France-based investment firm focused on healthcare, closed its second fund, at €315m.
The Med II fund went through a four-month fundraising campaign with LPs including nearly 30 investors such as endowments, foundations, funds-of-funds, family offices, banks, insurers and sovereign wealth funds investors, mainly from the United States and Europe.
Formed in 2014 by former 3i Healthcare leaders, ArchiMed is a lower midmarket private equity firm focused exclusively on healthcare investments, engaging in both unleveraged growth investments and leveraged buyouts. It invests between €5m and €50m per transaction in all healthcare sectors, including Medtech, Biopharma, Care Services and Preventive Healthcare.
Led by Denis Ribon, Vincent Guillaumot, Robin Filmer-Wilson, Loïc Kubitza and operating partner Christoph Böhmer, ArchiMed is currently the reference shareholder of Swiss-Italian company Medistream, French firms Polyplus and Fytexia, British firms Deallus and RehabWorks, Italian-French company Micromed and Italian company Primo.
The inaugural Med I fund raised €150m.